Clinical outcomes of upadacitinib dose escalation in inflammatory bowel disease: A single-center retrospective cohort study.

World J Gastrointest Pharmacol Ther · 2026 · PMC13248176 · PMID 42273244

Europe PMC DOI

hedged sentence

0.0940

closest p · 1.9× alpha

0.0940

boldest claim

The sentences

did not reach statistical significanceP = 0.094so close (0.05 < p ≤ 0.1)

Change in number of events per patient was analyzed using the Wilcoxon signed-rank test and did not reach statistical significance ( P = 0.094).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.